Claris Bio

About Claris Bio

Claris Bio is dedicated to improving lives by addressing unmet needs in ophthalmology through robust science and data-driven decision-making, with a focus on leading advancements in corneal therapy.

Products & Services

CSB-001:A topical ocular biologic solution of dHGF (hepatocyte growth factor), aimed at restoring structural and functional corneal integrity for eyes with Limbal Stem Cell Deficiency (LCSD).

CSB-001 (oremepermin alfa ophthalmic solution)

Specialties

Corneal therapy Ophthalmology drug development Hepatocyte growth factor (HGF) research Limbal Stem Cell Deficiency (LCSD) treatment Ophthalmic therapeutics Limbal stem cell deficiency (LSCD) treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 118000000 MR: - FA: $118M FAN: 118000000	D: 2026-07-28 FD: 2026-07-28	9 investors
2	RT: Series A T: - FT: Series A	A: 57000000 MR: - FA: 57 million FAN: 57000000	D: 2024-01-04 FD: 2024-01-04	4 investors

Series B Latest

2026-07-28

$118.0M

9 investors (Pro only)

Series A 2024-01-04

$57.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News

Claris Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised